|
Nivolumab in advanced melanoma treament |
Tapia-López E, Ciapponi A, Gonzalez L, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, López A, Rey-Ares L |
|
|
Citation Tapia-López E, Ciapponi A, Gonzalez L, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, López A, Rey-Ares L. Nivolumab in advanced melanoma treament. Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rapida No. 480. 2016 Authors' conclusions Moderate quality evidence showed that the use of nivolumab, when compared with dacarbazine in patients with advanced melanoma (metastatic or inoperable) would increase survival rate at one year and progression-free survival as first line. Although its use as single-agent or in combination with ipilimumab showed an increased progression-free survival, the lack of information on its impact on overall survival or comparative studies against other current first line treatment options (pembrolizumab or BRAF inhibitors) limit its recommendation as treatment alternative.
Clinical practice guidelines recommend its use as an additional alternative for first and/or second line treatment. The health technology assessments identified differ regarding use recommendations of this drug.
Final publication URL www.iecs.org.ar Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal; Humans; Melanoma Language Published Spanish Country of organisation Argentina English summary An English language summary is available. Address for correspondence Institute for Clinical Effectiveness and Health Policy, Viamonte 2146 - 3 Piso, C1056ABH Ciudad de Buenos Aires, Argentina Tel: +54 11 49 66 00 82 Fax:+54 11 49 53 40 58 Email: info@iecs.org.ar AccessionNumber 32016001132 Date abstract record published 02/12/2016 |
|
|
|